CSIMarket
 


Seagen Inc   (SGEN)
Other Ticker:  
 

Cumulative Seagen Inc 's Working Capital Ratio for Trailing Twelve Months Period

SGEN's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

SGEN Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth 31.5 % 25.37 % 34.24 % 43.87 % 3.95 %
Y / Y Current Assets Growth -7.54 % -9.46 % -6.11 % -2.32 % -11.4 %
Working Capital Ratio for Trailing Twelve Months Period 3.22 3.54 3.82 4.14 4.59
Total Ranking # 1106 # 1084 # 1076 # 1151 # 1081
Seq. Current Liabilities Growth 25.14 % 6.96 % -12.85 % 12.73 % 19.31 %
Seq. Current Assets Growth 1.43 % -3.31 % -7.16 % 1.56 % -0.69 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to growth in Current Liabilities in the III. Quarter to $955 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 3.22 below Seagen Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 124 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Seagen Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about SGEN
Working Capital Ratio SGEN in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 125
Sector # 643
S&P 500 # 1372


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
6.48 4.49 3.13
(Sep 30 2021)   (June 30. 2015)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Elevation Oncology inc   8.78 
Pluri Inc   8.72 
Humacyte Inc   8.63 
Surrozen Inc   8.57 
Ginkgo Bioworks Holdings Inc   8.38 
Biontech Se  8.26 
Tscan Therapeutics Inc   8.23 
Curis Inc   7.99 
Black Diamond Therapeutics Inc   7.94 
Entera Bio Ltd   7.73 
Atyr Pharma Inc   7.69 
Dbv Technologies S a   7.65 
Tenaya Therapeutics Inc   7.50 
Jounce Therapeutics inc   7.43 
Inhibikase Therapeutics Inc   7.42 
Editas Medicine Inc   7.35 
Compugen Ltd  7.23 
Vir Biotechnology Inc   7.15 
Prime Medicine Inc   6.98 
Renovacor Inc   6.79 
Kodiak Sciences Inc   6.72 
Senti Biosciences Inc   6.70 
Surface Oncology Inc   6.65 
Bioatla Inc   6.60 
C4 Therapeutics Inc   6.60 
Polarityte Inc   6.52 
Halozyme Therapeutics Inc   6.44 
Palisade Bio Inc   6.38 
In8bio Inc   6.34 
Adma Biologics Inc   6.33 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com